RESEARCHER PROFILE
Georgina Hughes,
Pharmacist & PhD Candidate
University of South Australia Clinical and Health Sciences
Registry of Senior Australians (ROSA)
South Australian Health and Medical Research Institute
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.
The study, published in the Journal of American Medical Directors Association (JAMDA), was led by Georgina, in collaboration with Professor Maria Inacio and Associate Professor Janet Sluggett. It’s Australia’s first national study investigating the use of antidepressants among older people living in residential aged care homes across the country, analysing the de-identified data of 779,659 residents from 3,371 aged care homes, between 2006 and 2019.
“We found antidepressants were used by 46.1% of residents in 2006 and this increased to 58.5% of residents in 2019,” Ms Hughes said.
“Nearly six in every ten residents of aged care homes are using an antidepressant, which is much higher than use in the general older population.”
The use of antidepressant medicines among older people in aged care homes in Australia is high, and there is a need for better mental health support and safer use of antidepressants to improve clinical care and health outcomes for older people.
Antidepressant medicines can have side effects, especially in older people, and Australia is one of the largest consumers globally.
Almost 60% of aged care home residents are using antidepressant medicines, prompting the need to investigate the reasons for such high usage.
Georgina talks to how big data is crucial in understanding and improving the use of antidepressant medicines in aged care, leading to better clinical care and health outcomes for older people in Australia.
Georgina is passionate about practice-informing, translational and innovative research to improve quality use of medicines and health outcomes.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
